CFTR and cystic fibrosis: In this scenario, the identification of agents endowed with a dual-target activity (i.e., antibacterial and antioxidant or antioxidant and CFTR-rescuing activities combined in one molecule) may lead to increased therapeutic benefits for cystic fibrosis patients [60].